No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BMY240628C44000
- 0.01
- 0.000.00%
15min DelayClose Jun 28 15:38 ET
0.02High0.01Low
0.02Open0.01Pre Close81 Volume1.52K Open Interest44.00Strike Price111.00Turnover487.49%IV5.97%PremiumJun 28, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.0227Delta0.0453Gamma4153.00Leverage Ratio-2.3439Theta0.0000Rho94.38Eff Leverage0.0001Vega
Intraday
- 5D
- Daily
News
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
On Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo Nordisk A/S (NYSE:NVO).Under the terms, Novo Nordisk has acquired the Hemophilia A program and rights to 2
Purple Biotech Says Interim Data From Pancreatic Cancer Drug Study Shows Promise
Purple Biotech (PPBT) said Thursday that additional interim data from a mid-stage study of its experimental drug CM24, combined with Bristol Myers Squibb's (BMY) nivolumab and chemotherapy for pancrea
Novo Nordisk Buys 2seventy Bio's Hemophilia A Program
Nvidia's a Smokescreen, This Is What Matters for Markets, Fed, Trump, and Biden. And 4 Other Things to Know Today. -- Barrons.com
Political junkies are well prepared for plenty of finger-pointing at the presidential debate on Thursday -- including on inflation. Four years after Covid-19 and the pandemic response ushered consumer
2seventy Bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours
2seventy bio (TSVT) said late Wednesday it has sold its Hemophilia A program and rights to its in-vivo gene-editing technology outside of oncology and gene-editing for autologous or allogeneic cell th
Comments
🔥 3 PDUFA decisions this week! 👇
📌 This week’s PDUFAs:
$Merck & Co(MRK.US$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma(VRNA.US$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab(GMAB.US$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co(MRK.US$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...
📌 This week’s PDUFAs:
$Merck & Co(MRK.US$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma(VRNA.US$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab(GMAB.US$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co(MRK.US$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...
7
$Viking Therapeutics(VKTX.US$ : “I’m a Lilly guy...To go up against Lilly is very, very hard.”
$CAVA Group(CAVA.US$ : “Cava feels like it has the possibility of being a Chipotle. So, even though I know it just had a big spike, I would not abandon it. I would just look to buy more if it came down.”
$Rubrik(RBRK.US$ : “It’s a good company, but the problem is, again, this market hates enterprise software.”
$Forward Air(FWRD.US$ : “There’s g...
$CAVA Group(CAVA.US$ : “Cava feels like it has the possibility of being a Chipotle. So, even though I know it just had a big spike, I would not abandon it. I would just look to buy more if it came down.”
$Rubrik(RBRK.US$ : “It’s a good company, but the problem is, again, this market hates enterprise software.”
$Forward Air(FWRD.US$ : “There’s g...
From YouTube
$Sarepta Therapeutics(SRPT.US$ : ELEVIDYS
$Harmony Biosciences(HRMY.US$ : WAKIX (pitolisant)
$Bristol-Myers Squibb(BMY.US$ : KRAZATI (Adagrasib) + Cetuximab
$argenx SE(ARGX.US$ : VYVGART Hytrulo (Efgartigimod)
$Merck & Co(MRK.US$ : Patritumab deruxtecan
$Verona Pharma(VRNA.US$ : Ensifentrine (Nebulized)
$Rocket Pharmaceuticals(RCKT.US$ : KRESLADI (Marnetegragene autotemcel)
$Harmony Biosciences(HRMY.US$ : WAKIX (pitolisant)
$Bristol-Myers Squibb(BMY.US$ : KRAZATI (Adagrasib) + Cetuximab
$argenx SE(ARGX.US$ : VYVGART Hytrulo (Efgartigimod)
$Merck & Co(MRK.US$ : Patritumab deruxtecan
$Verona Pharma(VRNA.US$ : Ensifentrine (Nebulized)
$Rocket Pharmaceuticals(RCKT.US$ : KRESLADI (Marnetegragene autotemcel)
14
Background and Recent Performance
$Bristol-Myers Squibb(BMY.US$ is a global biopharmaceutical company known for its innovative treatments in oncology, immunology, and cardiovascular diseases. Over the past year, BMY has faced some challenges, with its stock price nearing its 52-week low. As of June 20, 2024, the stock is trading at $40.795, which is close to its 52-week low of around $40.00.
$Bristol-Myers Squibb(BMY.US$
Despite recent performance s...
$Bristol-Myers Squibb(BMY.US$ is a global biopharmaceutical company known for its innovative treatments in oncology, immunology, and cardiovascular diseases. Over the past year, BMY has faced some challenges, with its stock price nearing its 52-week low. As of June 20, 2024, the stock is trading at $40.795, which is close to its 52-week low of around $40.00.
$Bristol-Myers Squibb(BMY.US$
Despite recent performance s...
12
$Bristol-Myers Squibb(BMY.US$
FDA Approves Augtyro (repotrectinib) 🎉
⇨ next-gen. Tyrosine Kinase Inhibitor (TKI) ⚛️
⇨ the only FDA-approved treatment for NTRK-positive tumors 👏
⇨ accelerated approval (sNDA) marks its 2nd indication in the US
⇨ based on Ph1/2 TRIDENT-1 trial 🧫
» effective in both TKI-naïve & TKI-pretreated patients across solid tumors
» showed significant response rates
FDA Approves Augtyro (repotrectinib) 🎉
⇨ next-gen. Tyrosine Kinase Inhibitor (TKI) ⚛️
⇨ the only FDA-approved treatment for NTRK-positive tumors 👏
⇨ accelerated approval (sNDA) marks its 2nd indication in the US
⇨ based on Ph1/2 TRIDENT-1 trial 🧫
» effective in both TKI-naïve & TKI-pretreated patients across solid tumors
» showed significant response rates
5
Read more